Financial Performance - In the first half of 2024, the company's operating revenue increased by 67.10% to approximately CNY 256.28 million compared to CNY 153.37 million in the same period last year[21]. - The net profit attributable to shareholders decreased by CNY 18.55 million, while the net profit after deducting non-recurring gains and losses decreased by CNY 99.06 million compared to the previous year[22]. - The basic earnings per share decreased by CNY 0.06 to -CNY 0.25, and the diluted earnings per share also decreased by CNY 0.06 to -CNY 0.25[21]. - The weighted average return on net assets decreased by 2.91 percentage points to -7.26% compared to the same period last year[21]. - The company reported a total profit of -71.29 million yuan and a net profit attributable to shareholders of -76.34 million yuan due to continuous price declines in the photovoltaic industry[57]. - The total comprehensive loss for the first half of 2024 was RMB 75.40 million, compared to a loss of RMB 56.27 million in the first half of 2023[152]. - The company reported a decrease in comprehensive income totaling CNY -76,335,164.46 for the current period[165]. - The net loss attributable to shareholders for the first half of 2024 was RMB 76.34 million, compared to a net loss of RMB 57.79 million in the first half of 2023, reflecting a deterioration in profitability[152]. Assets and Liabilities - The total assets decreased by 8.03% to approximately CNY 3.60 billion from CNY 3.92 billion at the end of the previous year[24]. - The company's total assets at the end of the reporting period amounted to CNY 1,298,188,040.76[168]. - The total liabilities decreased from ¥2,815,714,892.79 in December 2023 to ¥2,577,917,406.59 in June 2024, a decrease of approximately 8.4%[149]. - The total equity attributable to shareholders decreased from ¥1,096,302,645.86 in December 2023 to ¥1,018,602,356.32 in June 2024, a decline of about 7.1%[149]. - The company's long-term borrowings increased by 42.90% to 227,848,277.50 RMB, reflecting its funding strategy for photovoltaic projects[64]. Cash Flow - The company reported a net cash flow from operating activities of -CNY 121.15 million, compared to -CNY 116.47 million in the same period last year[24]. - The net cash flow from operating activities for the first half of 2024 was -121,154,538.82 RMB, compared to -116,465,392.74 RMB in the same period of 2023, indicating a slight deterioration[157]. - Cash inflow from financing activities totaled 523,541,380.02 RMB in 2024, down from 1,060,925,600.00 RMB in 2023, representing a decline of approximately 50.7%[158]. - The ending cash and cash equivalents balance decreased to 236,392,510.11 RMB in 2024 from 574,777,252.30 RMB in 2023, a decline of about 58.8%[158]. Business Operations - The company attributed the revenue increase primarily to the new photovoltaic business launched in the second half of 2023, which contributed to the revenue growth[21]. - The company faced losses in its photovoltaic business due to intensified competition and a mismatch in supply and demand, leading to a decline in product prices[22]. - The company continues to maintain profitability in its original medical segment despite the challenges in the photovoltaic sector[22]. - The company operates in the medical information technology industry, which is projected to reach an IT expenditure of 84.57 billion RMB by 2025[27]. - The company has expanded into the assisted reproductive medicine sector, with 602 approved medical institutions as of December 2023, amid a rising infertility rate of 12%-18%[29]. Research and Development - Research and development expenses increased to RMB 30.86 million, up 42.3% from RMB 21.69 million in the previous year, indicating a focus on innovation[151]. - The company is committed to continuous R&D for new technologies and products to maintain its competitive edge in the fast-evolving software market[77]. - The company is actively collaborating with research institutions and industry partners to enhance R&D in areas such as AI and low-altitude economy[49]. Environmental Compliance - The company has established a fluorine wastewater treatment station and implemented online monitoring for wastewater discharge, ensuring compliance with environmental standards[98]. - The company operates 13 sets of exhaust gas treatment facilities, including 5 for acidic waste gas and 2 for organic waste gas, to manage emissions effectively[98]. - The company has developed an emergency response plan for environmental incidents, which includes various drills conducted in the first half of 2024[100]. - The company promotes energy conservation and resource utilization through initiatives such as the use of geothermal heat pump systems in its headquarters[102]. Governance and Compliance - The company committed to maintaining independent financial operations, including establishing an independent financial department and accounting system[109]. - The company guarantees the independence of its management personnel, ensuring that senior executives do not hold positions in controlling entities[109]. - The company has established a governance structure to ensure independent decision-making and financial management[109]. - The company has committed to minimizing related party transactions, ensuring that any unavoidable transactions will adhere to market principles and legal requirements[109]. Market Position and Strategy - The company has developed a leading market position in clinical information systems, with its products implemented in nearly 2,400 medical institutions across 32 provinces in China[45]. - The company aims to enhance medical quality and efficiency through digital hospital solutions and smart medical decision-making[34]. - The company is focusing on market expansion and new product development as part of its strategic initiatives to improve future performance[151]. Risks and Uncertainties - The report includes a risk statement regarding forward-looking statements, highlighting uncertainties and potential investment risks[5]. - The company has identified risks related to market competition and price fluctuations in the photovoltaic industry, which could impact its business performance[78]. - Future performance may be adversely affected by changes in domestic and international policies, such as energy subsidies and trade protections, which could impact the solar industry significantly[80].

证券代码：603990 证券简称：麦迪科技 公告编号：2024-073 苏州麦迪斯顿医疗科技股份有限公司 第四届监事会第十一次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、 监事会会议召开情况 苏州麦迪斯顿医疗科技股份有限公司（以下简称"公司"）第四届监事会第 十一次会议于 2024 年 8 月 8 日在苏州工业园区归家巷 222 号麦迪科技公司 10 楼 会议室以现场结合通讯表决的方式召开。本次监事会会议通知于 2024 年 7 月 29 日以邮件形式发出。经全体监事一致推举，会议由职工代表监事马笑丹女士召集 并主持，会议应出席监事 3 名，实际出席监事 3 名，董事会秘书列席了本次会 议。会议召集及召开方式符合《中华人民共和国公司法》和《苏州麦迪斯顿医疗 科技股份有限公司章程》等有关规定，所形成的决议合法有效。 二、监事会会议审议情况 （一）审议并通过了《关于公司 2024 年半年度报告及摘要的议案》； 监事会认为：公司 2024 年半年度报告及报告摘要的相关内容编制程序符合 法律法规、规范性文件 ...

证券代码：603990 证券简称：麦迪科技 公告编号：2024-071 苏州麦迪斯顿医疗科技股份有限公司 公司预计将自本提示性公告披露日起六个月内披露本次交易相关的预案 或报告书（草案）。 一、 本次拟发生交易的基本情况 关于筹划重大资产重组的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 苏州麦迪斯顿医疗科技股份有限公司（以下简称"公司"）正在筹划重大 资产重组事项，拟出售公司所持绵阳炘皓新能源科技有限公司（以下简称"炘皓 新能源"）100%股权（以下简称"标的资产"）。 经初步研究和测算，预计本次交易将构成《上市公司重大资产重组管理 办法》规定的重大资产重组，不会导致公司控股股东和实际控制人发生变更。 本次交易的交易对手方及交易价格尚不确定，是否构成关联交易尚不确 定。本次交易以现金方式进行，不涉及发行股份。 本次交易目前尚处于筹划阶段，具体交易方案尚需进一步论证、沟通。 本次交易后续还需要按照相关法律、法规及公司章程的规定履行必要的内外部决 策和审批程序。本次交易相关事项尚存在重大的不确定性。 ...

证券代码：603990 证券简称：麦迪科技 公告编号：2024-070 苏州麦迪斯顿医疗科技股份有限公司 关于股份回购实施结果暨股份变动的公告 方式首次回购股份的公告》（公告编号：2024-011） （二）2024 年 8 月 2 日，公司完成回购，已实际回购公司股份 360.30 万股， 占公司总股本的 1.1764%，回购最高价格 8.86 元/股，回购最低价格 7.76 元/股， 回购均价 8.32 元/股，使用资金总额 2,996.62 万元。 （三）本次股份回购实施过程中，公司严格按照中国证监会《上市公司股份回 购规则》、上海证券交易所《上市公司自律监管指引第 7 号——回购股份》等有关 规定及公司董事会审议通过的回购方案内容执行。公司回购方案实际执行情况与 原披露的回购方案一致，不存在差异，公司已按披露的方案完成回购。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。。 重要内容提示： | 回购方案首次披露日 | 2024/2/7 | | | | | | | | | --- | --- | --- | --- | - ...

证券代码：603990 证券简称：麦迪科技 公告编号：2024-069 苏州麦迪斯顿医疗科技股份有限公司 医疗科技股份有限公司第三期员工持股计划（草案）》及其摘要的相关规定，上 述股票将予以锁定，锁定期12个月，自本次员工持股计划草案经公司股东大会审 议通过且公司公告最后一笔标的股票过户至本次员工持股计划名下之日起算，即 2024年7月24日起至2025年7月23日止，锁定期满后依据上一年度公司业绩目标考 核结果分配至持有人。 公司将持续关注本次员工持股计划的实施进展情况，并按照相关法律法规的 规定及时履行信息披露义务。敬请广大投资者注意投资风险。 特此公告。 苏州麦迪斯顿医疗科技股份有限公司董事会 苏州麦迪斯顿医疗科技股份有限公司（以下简称"公司"）于 2024 年 6 月 7 日、2024 年 6 月 24 日召开的第四届董事会第二十次会议、第四届监事会第十次 会议、2024 年第三次临时股东大会审议通过了《关于<苏州麦迪斯顿医疗科技股 份有限公司第三期员工持股计划（草案）>及其摘要的议案》《关于<苏州麦迪斯 顿医疗科技股份有限公司第三期员工持股计划管理办法（草案）>的议案》《关于 提请股东大会授权董事会 ...

证券代码：603990 证券简称：麦迪科技 公告编号：2024-068 苏州麦迪斯顿医疗科技股份有限公司 第三期员工持股计划第一次持有人会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、持有人会议召开情况 苏州麦迪斯顿医疗科技股份有限公司（以下简称"公司"）于 2024 年 7 月 12 日以现场结合通讯表决的方式召开了第三期员工持股计划（以下简称"本次员工 持股计划"或"持股计划"）第一次持有人会议（以下简称"持有人会议"或"会 议"）。会议出席持有人 20 名，代表员工持股计划持有份额 103.73 万份。 本次会议由董事会秘书李孟豪先生主持。会议的召集、召开和表决程序符合 《公司第三期员工持股计划（草案）》及其摘要和《公司第三期员工持股计划管 理办法（草案）》的有关规定。 二、持有人会议审议情况 （一）审议通过《关于设立苏州麦迪斯顿医疗科技股份有限公司第三期员工 持股计划管理委员会的议案》 为了促进本次员工持股计划日常管理的效率，根据《苏州麦迪斯顿医疗科技 股份有限公司第三期员工持股计划（草案）》及其摘要 ...

证券代码：603990 证券简称：麦迪科技 公告编号：2024-067 一、 回购股份的基本情况 公司于 2024 年 2 月 6 日召开第四届董事会第十五次会议，会议审议通过了《关 于公司以集中竞价交易方式回购股份方案的议案》，同意公司以自有资金通过集中 竞价交易方式回购公司已发行的部分人民币普通股（A 股）股票，拟用于实施员工 持股计划。回购资金总额不低于人民币 1,500 万元（含），不高于人民币 3,000 万 元（含），回购价格不高于人民币 16 元/股（含），回购期限为自董事会审议通过 回购股份方案之日起至 2024 年 8 月 5 日。具体内容详见公司于 2024 年 2 月 7 日 披露的《麦迪科技关于以集中竞价交易方式回购股份的报告书暨落实"提质增效 重回报"行动方案的公告》（公告编号：2024-010） 二、 回购股份的进展情况 根据中国证监会《上市公司股份回购规则》《上海证券交易所上市公司自律监 苏州麦迪斯顿医疗科技股份有限公司 关于以集中竞价交易方式回购公司股份比例达到 1%暨 回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的 ...

Revenue Expectations - The company expects a revenue of between 245 million to 265 million CNY for the first half of 2024, compared to 153.37 million CNY in the same period last year, indicating a significant growth[4]. - The increase in revenue is attributed to the profitability of the medical information and services business, despite losses in the photovoltaic sector due to declining product prices[7]. Profit Projections - The net profit attributable to the parent company is projected to be between -50 million to -75 million CNY for the first half of 2024, compared to -57.79 million CNY in the same period last year, indicating continued losses[4]. - The net profit attributable to the parent company, after deducting non-recurring gains and losses, is expected to be between -120 million to -165 million CNY for the first half of 2024[4]. - The company reported a total profit of -49.53 million CNY and a net profit of -57.79 million CNY for the first half of 2023[6]. Financial Forecast Reliability - The company emphasizes that there are no significant uncertainties that could affect the accuracy of this earnings forecast[8]. - The preliminary financial data provided is subject to final confirmation in the official half-year report[9].

关于上海证券交易所 《关于对苏州麦迪斯顿医疗科技股份有限公司 2023 年年度报告的信息披露监管工作函》 有关财务问题回复的专项说明 中国杭州市钱江新城新业路 8 号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road，Qianjiang New City,Hangzhou Tel.0571-88879999 Fax.0571-88879000 www.zhcpa.cn 有关财务问题回复的专项说明 T 中汇会专[2024]9205 号 公司回复: 上海证券交易所: (一) 玛丽医院收购后历年门诊量、诊疗人数、收费标准、员工类别及数量等主要经 营数据,说明其财务数据是否与经营数据相匹配,是否符合行业趋势,本期收入增长但业 绩下滑的原因及合理性: 由苏州麦迪斯顿医疗科技股份有限公司 (以下简称公司或麦迪科技公司)转 来的贵所于 2024 年 5 月 20 日下发的《关于对苏州麦迪斯顿医疗科技股份有限 公司 2023 年年度报告的信息披露监管工作函》(上证公函【0590】号,以下简 称工作 ...

关于上海证券交易所 《关于对苏州麦迪斯顿医疗科技股份有限公司 2023 年年度报告的信息披露监管工作函》 有关财务问题回复的专项说明 中国杭州市钱江新城新业路 8 号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road，Qianjiang New City,Hangzhou Tel.0571-88879999 Fax.0571-88879000 www.zhcpa.cn 关于上海证券交易所 《关于对苏州麦迪斯顿医疗科技股份有限公司 2023 年年度报告的信息披露监管工作函》 有关财务问题回复的专项说明 中汇会专[2024]9205 号 上海证券交易所: 由苏州麦迪斯顿医疗科技股份有限公司 (以下简称公司或麦迪科技公司)转 来的贵所于 2024 年 5 月 20 日下发的《关于对苏州麦迪斯顿医疗科技股份有限 公司 2023 年年度报告的信息披露监管工作函》(上证公函【0590】号,以下简 称工作函)奉悉。我们作为苏州麦迪斯顿医疗科技股份有限公司年报会计师，对 问询函中需要我们回复的财务 ...